Analyze Diet

Topic:Vaccine development

Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals.
Vaccine    August 3, 2008   Volume 26, Issue 39 5014-5021 doi: 10.1016/j.vaccine.2008.07.037
von Teichman BF, Smit TK.The polyvalent African Horsesickness (AHS) attenuated live vaccine (ALV) produced by Onderstepoort Biological Products (OBP) Ltd., South Africa, has been associated with some safety concerns and alleged cases of vaccine failure or vaccine-induced disease. The risk of reassortment and reversion to virulence is a common concern associated with the use of ALVs, and a phenomenon reported for viruses with segmented RNA genomes. The purpose of this study was to determine whether or not reassortment of AHS vaccine strains could result in reassortants and reversion to virulence and therefore cause AHS...
In vitro culture of equine respiratory mucosa explants.
Veterinary journal (London, England : 1997)    June 6, 2008   Volume 181, Issue 3 280-287 doi: 10.1016/j.tvjl.2008.03.027
Vandekerckhove A, Glorieux S, Broeck WV, Gryspeerdt A, van der Meulen KM, Nauwynck HJ.An in vitro model of the upper respiratory tract of the horse was developed to investigate mechanisms of respiratory diseases. Four tissues of the upper respiratory tract of three horses were collected. Explants were maintained in culture at an air-liquid interface for 96h. At 0, 24, 48, 72 and 96h of cultivation, a morphometric analysis was performed using light microscopy, scanning electron microscopy and transmission electron microscopy. The explants were judged on morphometric changes of epithelium, basement membrane and connective tissue. Viability was evaluated using a fluorescent Termin...
Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus.
Nature biotechnology    April 20, 2008   Volume 26, Issue 5 571-577 doi: 10.1038/nbt1400
Chang DC, Liu WJ, Anraku I, Clark DC, Pollitt CC, Suhrbier A, Hall RA, Khromykh AA.DNA vaccines encoding replication-defective viruses are safer than inactivated or live attenuated viruses but may fail to stimulate an immune response sufficient for effective vaccination. We augment the protective capacity of a capsid-deleted flavivirus DNA vaccine by co-expressing the capsid protein from a separate promoter. In transfected cells, the capsid-deleted RNA transcript is replicated and translated to produce secreted virus-like particles lacking the nucleocapsid. This RNA is also packaged with the help of co-expressed capsid protein to form secreted single-round infectious particl...
Collaborative study for the establishment of a candidate equine influenza subtype 2 American-like strain A/EQ/South Africa/4/03 – horse antiserum biological reference preparation.
Pharmeuropa bio    April 17, 2008   Volume 2007, Issue 1 7-14 
Daly J, Daas A, Behr-Gross ME.In 2004, the Office International des Epizooties (OIE) Expert Surveillance Panel on equine influenza recommended that the American lineage component (H3N8) of equine influenza vaccines (A/eq/Newmarket/1/93-like) be updated to an A/eq/South Africa/4/03-like virus. As a consequence the common European Pharmacopoeia (Ph. Eur.) - OIE reference for equine influenza subtype 2 American-like antiserum had to be complemented by an antiserum raised in horses against an A/eq/South Africa/4/03 strain. An international collaborative study run by the European Directorate for the Quality of Medicines (EDQM) ...
Australian equine influenza: vaccine protection in the UK.
The Veterinary record    April 15, 2008   Volume 162, Issue 15 491-492 doi: 10.1136/vr.162.15.491-b
Bryant N, Rash A, Lewis N, Elton D, Montesso F, Ross J, Newton R, Paillot R, Watson J, Jeggo M.No abstract available
Chimeric vapA/groEL2 DNA vaccines enhance clearance of Rhodococcus equi in aerosol challenged C3H/He mice.
Vaccine    April 3, 2008   Volume 26, Issue 20 2457-2465 doi: 10.1016/j.vaccine.2008.03.015
Phumoonna T, Barton MD, Vanniasinkam T, Heuzenroeder MW.Rhodococcus equi remains a significant bacterial pathogen, causing severe pyogranulomatous pneumonia in foals aged 1-3 months. There is no effective vaccine currently available for the prevention of R. equi pneumonia. DNA vaccines are known to offer specific advantages over conventional vaccines. The aim of this study was to demonstrate efficacy of our recombinant DNA vaccine candidates, namely pcDNA3-Re1, pcDNA3-Re3 and pcDNA3-Re5 by combining a heat shock protein GroEL2 to a virulence-associated protein A (VapA) from R. equi to protect C3H/He mice against the R. equi infection. VapA was show...
[Design of equine serum-based Marburg virus immunoglobulin].
Voprosy virusologii    March 6, 2008   Volume 53, Issue 1 39-41 
Borisevich IV, Potryvaeva NV, Mel'nikov SA, Evseev AA, Krasnianskiĭ VP, Maksimov VA.Immunoglobulin (Ig) against Marburg fever (MF) has been obtained from the equine serum. In terms of physicochemical and immunobiological properties, the obtained preparation corresponds to the quality of heterologous commercial immunoglobulins. The application of Marburg virus (MV) Ig with a titer of no less than 1:2048 by the emergency prevention scheme 1-2 hours after intraperitoneal inoculation of guinea pigs with MV in a dose of 20-50 LD50 protected 88-100% of the animals from death. MV Ig is recommended for emergency prevention of human MF.
Ovine anti-rabies antibody production and evaluation.
Comparative immunology, microbiology and infectious diseases    February 19, 2008   Volume 32, Issue 1 9-19 doi: 10.1016/j.cimid.2007.11.004
Redwan el-RM, Fahmy A, El Hanafy A, Abd El-Baky N, Sallam SM.In view of the disadvantages of human and equine rabies immunoglobulin still there is urgent needs for safe and cost-control anti-rabies immunoglobulins especially for person who have been severely exposed (categories III) to the virus. Our attempt to produce a less immunogenic and cheaper anti-rabies immunoglobulin affordable for those people living in developing countries, has been harnessed the ovine as a bioreactor instead the horse. The animals have been intramuscular immunized, and the plasma processed with 5% caprylic acid to yield IgG with purity of 95%. Moreover, antibody apparently i...
A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
Veterinary immunology and immunopathology    February 16, 2008   Volume 123, Issue 3-4 230-239 doi: 10.1016/j.vetimm.2008.02.002
El Garch H, Minke JM, Rehder J, Richard S, Edlund Toulemonde C, Dinic S, Andreoni C, Audonnet JC, Nordgren R, Juillard V.Successful vaccination against West Nile virus (WNV) requires induction of both neutralizing antibodies and cell-mediated immune responses. In this study, we have assessed the ability of a recombinant ALVAC-WNV vaccine (RECOMBITEK WNV) to elicit neutralizing antibodies and virus-specific cell-mediated immune responses in horses. In addition, we examined whether prior exposure to ALVAC-WNV vaccine would inhibit B and cell-mediated immune responses against the transgene product upon subsequent booster immunizations with the same vaccine. The results demonstrated that the recombinant ALVAC-WNV va...
Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.
Veterinary research    February 7, 2008   Volume 39, Issue 3 21 doi: 10.1051/vetres:2007062
Paillot R, Grimmett H, Elton D, Daly JM.In the horse, conventional inactivated or subunit vaccines against equine influenza virus (EIV) induce a short-lived antibody-based immunity to infection. Alternative strategies of vaccination have been subsequently developed to mimic the long-term protection induced by natural infection with the virus. One of these approaches is the use of immune-stimulating complex (ISCOM)-based vaccines. ISCOM vaccines induce a strong antibody response and protection against influenza in horses, humans, and a mouse model. Cell-mediated immunity (CMI) has been demonstrated in humans and mice after ISCOM vacc...
Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.
Journal of virology    January 30, 2008   Volume 82, Issue 8 4052-4063 doi: 10.1128/JVI.02028-07
Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, Montelaro RC.A highly effective attenuated equine infectious anemia virus (EIAV) vaccine (EIAV(D9)) capable of protecting 100% of horses from disease induced by a homologous Env challenge strain (EIAV(PV)) was recently tested in ponies to determine the level of protection against divergent Env challenge strains (J. K. Craigo, B. S. Zhang, S. Barnes, T. L. Tagmyer, S. J. Cook, C. J. Issel, and R. C. Montelaro, Proc. Natl. Acad. Sci. USA 104:15105-15110, 2007). An inverse correlation between challenge strain Env variation and vaccine protection from disease was observed. Given the striking differences in pro...
Virus recovery rates for wild-type and live-attenuated vaccine strains of African horse sickness virus serotype 7 in orally infected South African Culicoides species.
Medical and veterinary entomology    December 21, 2007   Volume 21, Issue 4 377-383 doi: 10.1111/j.1365-2915.2007.00706.x
Venter GJ, Paweska JT.Previously reported virus recovery rates from Culicoides (Avaritia) imicola Kieffer and Culicoides (Avaritia) bolitinos Meiswinkel (Diptera, Ceratopogonidae) orally infected with vaccine strain of African horse sickness virus serotype 7 (AHSV-7) were compared with results obtained from concurrently conducted oral infections with five recent AHSV-7 isolates from naturally infected horses from various localities in South Africa. Culicoides were fed sheep bloods spiked with 10(7.6) TCID(50)/mL of a live-attenuated vaccine strain AHSV-7, and with five field isolates in which virus titre in the blo...
Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles.
The Journal of general virology    December 20, 2007   Volume 89, Issue Pt 1 138-147 doi: 10.1099/vir.0.83266-0
Mattil-Fritz S, Scharner D, Piuko K, Thönes N, Gissmann L, Müller H, Müller M.Equine sarcoids are fibrosarcoma-like skin tumours with a prevalence of approximately 1-2 %. Strong evidence exists for a causative role of bovine papillomavirus (BPV) type 1 or type 2 in the development of sarcoids. No effective treatment of equine sarcoid is available and after surgical excision relapse of the tumours is very frequent. We developed chimeric virus-like particles (CVLPs) of BPV 1 L1-E7 for the immunotherapy of equine sarcoid. In a phase I clinical trial 12 horses suffering from equine sarcoid with an average number of more than 22 tumours per animal were vaccinated in a dose-e...
Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1.
The Journal of general virology    December 20, 2007   Volume 89, Issue Pt 1 148-157 doi: 10.1099/vir.0.83267-0
Ashrafi GH, Piuko K, Burden F, Yuan Z, Gault EA, Müller M, Trawford A, Reid SWJ, Nasir L, Campo MS.Equine sarcoids are fibroblastic skin tumours affecting equids worldwide. While the pathogenesis is not entirely understood, infection with bovine papillomavirus (BPV) type 1 (and less commonly type 2) has been implicated as a major factor in the disease process. Sarcoids very seldom regress and in fact often recrudesce following therapy. Nothing is known about the immune response of the equine host to BPV. Given that the viral genes are expressed in sarcoids, it is reasonable to assume that vaccination of animals against the expressed viral proteins would lead to the induction of an immune re...
Equine travellers to the Olympic Games in Hong Kong 2008: a review of worldwide challenges to equine health, with particular reference to vector-borne diseases.
Equine veterinary journal    December 18, 2007   Volume 40, Issue 1 87-95 doi: 10.2746/042516408X253136
Herholz C, Füssel AE, Timoney P, Schwermer H, Bruckner L, Leadon D.The past 10-20 years have seen exponential growth in the volume of trade in horses and equine germplasm; and the extent of global horse movements has increased significantly in the last 4 years. In preparing for the transport of elite Olympic horses to Hong Kong in 2008, it will be very important to be as fully informed as possible of the disease situation in both the exporting and importing country, import and re-entry requirements, as well as having a vaccination strategy to protect against particular diseases. In this context the review describes the equine vector-borne disease situation in...
The evolving means of protecting horses against West Nile infection through immunisation.
Equine veterinary journal    December 11, 2007   Volume 39, Issue 6 484-485 doi: 10.2746/042516407X247116
Traub-Dargatz JL, Cordes T, Evans MB.No abstract available
Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
Equine veterinary journal    December 11, 2007   Volume 39, Issue 6 486-490 doi: 10.2746/042516407X214473
Long MT, Gibbs EP, Mellencamp MW, Zhang S, Barnett DC, Seino KK, Beachboard SE, Humphrey PP.West Nile virus (WNV) infection is endemic and able to cause disease in naive hosts. It is necessary therefore to evaluate the safety of new vaccines. Objective: To establish: 1) the safety of a modified live Flavivirus/West Nile virus (WN-FV) chimera by administration of an overdose and testing for shed of vaccine virus and spread to uninoculated sentinel horses; 2) that this vaccine did not become pathogenic once passaged in horses; and 3) vaccine safety under field conditions. Methods: There were 3 protocols: 1) In the overdose/shed and spread study, horses were vaccinated with a 100x immun...
Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
Equine veterinary journal    December 11, 2007   Volume 39, Issue 6 491-497 doi: 10.2746/042516407X217416
Long MT, Gibbs EP, Mellencamp MW, Bowen RA, Seino KK, Zhang S, Beachboard SE, Humphrey PP.West Nile virus (WNF) is a Flavivirus responsible for a life-threatening neurological disease in man and horses. Development of improved vaccines against Flavivirus infections is therefore important. Objective: To establish that a single immunogenicity dose of live Flavivirus chimera (WN-FV) vaccine protects horses from the disease and it induces a protective immune response, and to determine the duration of the protective immunity. Methods: Clinical signs were compared between vaccinated (VACC) and control (CTRL) horses after an intrathecal WNV challenge given at 10 or 28 days, or 12 months p...
Alternative vaccination against equine botulism (BoNT/C).
Equine veterinary journal    December 11, 2007   Volume 39, Issue 6 516-520 doi: 10.2746/042516407X236550
Frey J, Eberle S, Stahl C, Mazuet C, Popoff M, Schatzmann E, Gerber V, Dungu B, Straub R.In Europe the incidence of botulism in horses has increased in the last decade due to the growing popularity of haylage feeding. Recombinant vaccines are safer and less expensive to produce and are generally better tolerated than toxoids. Objective: To investigate whether the recombinant C-terminal half of the heavy chain of the botulinum neurotoxin C (Hc BoNT/C) in combination with an immunstimulatory adjuvant is an appropriate vaccine candidate for horses by testing its efficacy to induce neutralising antibodies and by comparing its immunogenic properties and adverse reactions to a commercia...
Glanders: off to the races with Burkholderia mallei.
FEMS microbiology letters    November 23, 2007   Volume 277, Issue 2 115-122 doi: 10.1111/j.1574-6968.2007.00949.x
Whitlock GC, Estes DM, Torres AG.Burkholderia mallei, the etiologic agent of the disease known as glanders, is primarily a disease affecting horses and is transmitted to humans by direct contact with infected animals. The use of B. mallei as a biological weapon has been reported and currently, there is no vaccine available for either humans or animals. Despite the history and highly infective nature of B. mallei, as well as its potential use as a bio-weapon, B. mallei research to understand the pathogenesis and the host responses to infection remains limited. Therefore, this minireview will focus on current efforts to elucida...
Safety and immunogenicity of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen Rhodococcus equi.
Vaccine    November 21, 2007   Volume 26, Issue 7 998-1009 doi: 10.1016/j.vaccine.2007.10.069
Lopez AM, Townsend HG, Allen AL, Hondalus MK.Rhodococcus equi causes serious pneumonia in neonatal foals and is an opportunistic pathogen of people with compromised cellular immunity. No effective vaccine against R. equi disease in foals is available. We tested the safety and immunogenicity of a live, fully attenuated riboflavin auxotrophic candidate vaccine strain of R. equi (R. equi rib-). We demonstrated that R. equi rib- is immunogenic and capable of inducing IFN-gamma responses in immunocompetent BALB/c mice, yet it is safe even in an immunocompromised SCID mouse infection model. Moreover, it protects immunocompetent mice against vi...
Genetic relatedness of recent Canadian equine influenza virus isolates with vaccine strains used in the field.
The Canadian veterinary journal = La revue veterinaire canadienne    November 9, 2007   Volume 48, Issue 10 1028-1030 
Gagnon CA, Elahi SM, Tremblay D, Lavoie JP, Bryant NA, Elton DM, Carman S, Elsener J.No abstract available
Monoclonal antibodies against the nucleocapsid proteins of henipaviruses: production, epitope mapping and application in immunohistochemistry.
Archives of virology    November 5, 2007   Volume 153, Issue 2 273-281 doi: 10.1007/s00705-007-1079-x
Xiao C, Liu Y, Jiang Y, Magoffin DE, Guo H, Xuan H, Wang G, Wang LF, Tu C.Four monoclonal antibodies (mAbs) were generated by immunizing BALB/C mice with recombinant nucleocapsid protein (N) of Nipah virus (NiV) and Hendra virus (HeV) expressed in E. coli. Two mAbs each were obtained for the HeV N and NiV N, respectively. All four mAbs displayed specific reactivity with the recombinant N proteins of both viruses by western blot, which was further confirmed by immunofluorescent antibody assay using fixed insect cells infected with recombinant baculoviruses expressing either the HeV or NiV N protein. Epitope mapping using a 12-mer random peptide phage display library ...
Seroprevalence and risk factors for infection with West Nile virus in Saskatchewan horses, 2003.
Canadian journal of veterinary research = Revue canadienne de recherche veterinaire    October 25, 2007   Volume 71, Issue 4 256-263 
Epp T, Waldner C, Leighton FA, Berke O, Townsend HG.The primary objectives of this study were to determine the seroprevalence of West Nile virus (WNV) infection of horses in Saskatchewan in 2003 and to identify risk factors for the infection. Blood samples were collected in August and October from 212 horses in 20 herds in 5 geographic zones. After accounting for within-herd clustering, the proportion of horses that had been infected with WNV, as determined by IgG and IgM antibody response, was 55.7% (95% confidence interval, 44.9% to 65.8%). The proportion of antibody-positive horses differed among herds (0% to 100%) and across ecoregions (20%...
Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.
Vaccine    October 15, 2007   Volume 25, Issue 49 8338-8345 doi: 10.1016/j.vaccine.2007.09.055
Samina I, Havenga M, Koudstaal W, Khinich Y, Koldijk M, Malkinson M, Simanov M, Perl S, Gijsbers L, Weverling GJ, Uytdehaag F, Goudsmit J.Studies were performed with an inactivated vaccine against the mosquito-borne flavivirus, West Nile virus (WNV). The mammalian cell line, PER.C6, was selected as the platform for WNV growth since both the neurovirulent strains NY99 and ISR98 that cause epidemics in humans and high mortality in geese, respectively, could be propagated to high titers (10(9) to 10(10)TCID(50)/ml) on these cells. Based on the high DNA homology of the WNV envelope (E) protein and non-structural protein 5 (NS5), and identical neurovirulence in mice and geese, we concluded that NY99 and ISR98 viruses are closely rela...
Preliminary study of mucosal IgA in the equine small intestine: specific IgA in cases of acute grass sickness and controls.
Equine veterinary journal    October 4, 2007   Volume 39, Issue 5 457-460 doi: 10.2746/042516407x193189
Nunn FG, Pirie RS, McGorum B, Wernery U, Poxton IR.There is much evidence to suggest that group III Clostridium botulinum (types C and D) are involved in the aetiology of equine grass sickness (EGS). Antibodies have been detected previously in the blood and high levels associated with resistance to disease. Specific mucosal antibodies in the gastrointestinal (GI) tract are likely to be important in protection, and this study was performed to ascertain if such antibodies could be detected and if their levels were related to disease state. Objective: To develop a method for quantifying IgA antibodies to C. botulinum types C and D in the GI tract...
Rhodococcus equi infection in foals: the science of ‘rattles’.
Equine veterinary journal    October 4, 2007   Volume 39, Issue 5 470-478 doi: 10.2746/042516407x209217
Muscatello G, Leadon DP, Klayt M, Ocampo-Sosa A, Lewis DA, Fogarty U, Buckley T, Gilkerson JR, Meijer WG, Vazquez-Boland JA.Infection with Rhodococcus (Corynebacterium) equi is a well-recognised condition in foals that represents a consistent and serious risk worldwide. The condition manifests itself primarily as one of pulmonary abscessation and bronchitis, hence the terminology of 'rattles' derived from its most obvious clinical sign, frequently terminal when first identified. This review addresses the clinical manifestation, bacteriology and pathogenesis of the condition together with recent developments providing knowledge of the organism in terms of virulence, epidemiology, transmission and immune responses. E...
Equine influenza vaccine containing older H3N8 strains offers protection against A/eq/South Africa/4/03 (H3N8) strain in a short-term vaccine efficacy study.
Equine veterinary journal    October 4, 2007   Volume 39, Issue 5 446-450 doi: 10.2746/042516407x180327
Daly JM, Sindle T, Tearle J, Barquero N, Newton JR, Corning S.Surveillance of equine influenza viruses has suggested that strains included in currently licensed vaccines are a poor match for those predominantly circulating in the field. Objective: To assess the ability of Duvaxyn IE-T Plus to provide cross protection against the newly evolved South Africa/4/03 (H3N8) strain of equine influenza virus. Methods: The vaccine efficacy was evaluated by challenge infection with influenza strain A/eq/South Africa/4/03 (H3N8) 2 weeks after a primary course of 2 vaccinations with Duvaxyn IE-T Plus given at a 4-week interval. The outcome of challenge in vaccinated ...
Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab’)(2) in macaque.
International immunopharmacology    October 4, 2007   Volume 7, Issue 13 1834-1840 doi: 10.1016/j.intimp.2007.09.011
Xu Y, Jia Z, Zhou L, Wang L, Li J, Liang Y, Zhao T, Ni B, Wu Y.To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')(2) requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')(2) fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')(2) or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this an...
Analysis of Venezuelan equine encephalitis virus capsid protein function in the inhibition of cellular transcription.
Journal of virology    October 3, 2007   Volume 81, Issue 24 13552-13565 doi: 10.1128/JVI.01576-07
Garmashova N, Atasheva S, Kang W, Weaver SC, Frolova E, Frolov I.The encephalitogenic New World alphaviruses, including Venezuelan (VEEV), eastern (EEEV), and western equine encephalitis viruses, constitute a continuing public health threat in the United States. They circulate in Central, South, and North America and have the ability to cause fatal disease in humans and in horses and other domestic animals. We recently demonstrated that these viruses have developed the ability to interfere with cellular transcription and use it as a means of downregulating a cellular antiviral response. The results of the present study suggest that the N-terminal, approxima...
1 16 17 18 19 20 34